METAGENOMI TECHNOLOGIES, LLC
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Metagenomi Technologies' stock with a target price of $19.8, indicating significant growth potential.
Financial Health
Metagenomi Technologies is performing well with strong revenue and cash flow, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MGX
Biotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: July 11, 2025
Explore BasketMicrobiome Modulators
Discover a carefully selected group of innovative biotechnology companies leveraging the untapped power of the body's microbiome. These pioneering firms are creating revolutionary therapies that target the root causes of disease by rebalancing our internal microbial ecosystems.
Published: June 17, 2025
Explore BasketPersonalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Published: June 17, 2025
Explore BasketNew Moon Portfolio
This collection represents the very beginning of the next technological cycle. These carefully selected companies are sowing the seeds of future industries, giving you early exposure to disruptive innovators poised for exponential growth as their technologies reshape our world.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Small-cap growth story
Early‑stage technology can offer upside if platforms validate, but small‑cap biotech stocks are typically volatile and fundraising may dilute shareholders.
Novel editing platforms
The company explores microbial‑derived gene‑editing systems that could be licenced or developed further, though scientific and regulatory hurdles remain.
Partnerships and deals
Collaborations or licensing agreements can de‑risk development and create revenue paths, yet progress depends on successful R&D and approvals.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
